Remove Marketing Remove Production Remove Regulation
article thumbnail

DCGI issues alert on suspected falsified GLP-1-RA products in the market

AuroBlog - Aurous Healthcare Clinical Trials blog

The Central drug regulator has issued alert on suspected falsified versions of Glucagon-like peptide 1 receptor agonist (GLP-1-RA) products, an anti-diabetes management drug, in the market. GLP-1-RA […]

article thumbnail

AI in Pharma Marketing: Innovation or Compliance Nightmare?

Pharma Marketing Network

Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Brazilian pharma market: Key information and what may change

Pharmaceutical Technology

Brazil is the largest country in Latin America, with a population of over 212 million, and consequently has the biggest pharmaceutical market in the region. Advantages of joining PIC/S include the adoption of codes that should reduce the number of audits required for some products, accelerating their time to market.

Marketing 246
article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Worldwide Clinical Trials

Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. The process, from patient coordination through manufacturing and administration, is intricate, time-sensitive, and highly regulated.

article thumbnail

Amylyx, with GLP-1 buy, doubles down on blood sugar drugs

Bio Pharma Dive

Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

Drugs 201
article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

article thumbnail

FDA unveils comprehensive strategy for regulating AI in medical products

BioPharma Reporter

With the pharma and healthcare landscape increasingly being shaped by artificial intelligence (AI), the US Food and Drug Administration (FDA) has taken proactive steps to outline a comprehensive strategy for regulating AI in medical products.